Department of Genitourinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Curr Oncol Rep. 2024 Aug;26(8):945-958. doi: 10.1007/s11912-024-01555-0. Epub 2024 Jun 5.
This review sought to define the emerging roles of urinary tumor DNA (utDNA) for diagnosis, monitoring, and treatment of bladder cancer. Building from early landmark studies the focus is on recent studies, highlighting how utDNA could aid personalized care.
Recent research underscores the potential for utDNA to be the premiere biomarker in bladder cancer due to the constant interface between urine and tumor. Many studies find utDNA to be more informative than other biomarkers in bladder cancer, especially in early stages of disease. Points of emphasis include superior sensitivity over traditional urine cytology, broad genomic and epigenetic insights, and the potential for non-invasive, real-time analysis of tumor biology. utDNA shows promise for improving all phases of bladder cancer care, paving the way for personalized treatment strategies. Building from current research, future comprehensive clinical trials will validate utDNA's clinical utility, potentially revolutionizing bladder cancer management.
本综述旨在定义尿肿瘤 DNA(utDNA)在膀胱癌的诊断、监测和治疗中的新兴作用。从早期的里程碑式研究出发,重点关注最近的研究,强调 utDNA 如何能够帮助实现个性化护理。
最近的研究强调了 utDNA 作为膀胱癌首要生物标志物的潜力,因为尿液和肿瘤之间存在持续的相互作用。许多研究发现 utDNA 在膀胱癌中比其他生物标志物更具信息量,尤其是在疾病的早期阶段。重点包括比传统尿液细胞学具有更高的灵敏度、广泛的基因组和表观遗传学见解,以及对肿瘤生物学进行非侵入性、实时分析的潜力。utDNA 有望改善膀胱癌护理的所有阶段,为个性化治疗策略铺平道路。基于当前的研究,未来全面的临床试验将验证 utDNA 的临床实用性,有可能彻底改变膀胱癌的管理。